82,800 Shares in Cogent Biosciences, Inc. $COGT Bought by Maven Securities LTD

Maven Securities LTD bought a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 82,800 shares of the technology company’s stock, valued at approximately $2,941,000. Maven Securities LTD owned about 0.06% of Cogent Biosciences as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC raised its position in Cogent Biosciences by 1,164.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock worth $25,000 after purchasing an additional 652 shares during the last quarter. Global Retirement Partners LLC bought a new position in Cogent Biosciences during the 4th quarter worth $37,000. PNC Financial Services Group Inc. raised its position in Cogent Biosciences by 414.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the technology company’s stock worth $46,000 after purchasing an additional 1,032 shares during the last quarter. GAMMA Investing LLC raised its position in Cogent Biosciences by 91.7% during the 4th quarter. GAMMA Investing LLC now owns 1,369 shares of the technology company’s stock worth $49,000 after purchasing an additional 655 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Cogent Biosciences by 35.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the technology company’s stock worth $66,000 after purchasing an additional 488 shares during the last quarter.

Cogent Biosciences Stock Performance

Shares of Cogent Biosciences stock opened at $33.10 on Monday. The company has a current ratio of 15.14, a quick ratio of 15.14 and a debt-to-equity ratio of 0.41. The business has a 50-day moving average price of $34.62 and a two-hundred day moving average price of $36.57. The company has a market cap of $5.66 billion, a P/E ratio of -15.25 and a beta of 0.34. Cogent Biosciences, Inc. has a 1-year low of $6.88 and a 1-year high of $43.73.

Cogent Biosciences (NASDAQ:COGT) last issued its earnings results on Tuesday, May 5th. The technology company reported ($0.53) EPS for the quarter, meeting the consensus estimate of ($0.53). As a group, analysts anticipate that Cogent Biosciences, Inc. will post -2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Piper Sandler raised their target price on Cogent Biosciences from $39.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. HC Wainwright increased their price target on Cogent Biosciences to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Wedbush reiterated an “outperform” rating and set a $55.00 price target on shares of Cogent Biosciences in a report on Friday, May 29th. Jefferies Financial Group assumed coverage on Cogent Biosciences in a report on Monday, March 16th. They set a “buy” rating and a $55.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, April 10th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.73.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.